keyword
MENU ▼
Read by QxMD icon Read
search

Free psa

keyword
https://www.readbyqxmd.com/read/28523420/cost-utility-analysis-of-certolizumab-pegol-in-combination-with-methotrexate-in-patients-with-moderate-to-severe-active-rheumatoid-arthritis-in-greece
#1
C Tzanetakos, A Tzioufas, A Goules, G Kourlaba, T Theodoratou, P Christou, N Maniadakis
We aimed to evaluate the cost-effectiveness of certolizumab pegol (CZP), a pegylated fc-free anti-TNF, as add-on therapy to methotrexate (MTX) versus etanercept, adalimumab, or golimumab in patients with moderate-to-severe active rheumatoid arthritis (RA) not responding to the conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs). A Markov model (6-month cycle length) assessed health and cost outcomes of CZP versus other anti-TNFs recommended for RA in Greece over a patient's lifetime. Following discontinuation of first-line anti-TNF, patients switched to second anti-TNF and then to a biologic with another mode of action...
May 18, 2017: Rheumatology International
https://www.readbyqxmd.com/read/28523407/heterogeneous-oncologic-outcomes-according-to-surgical-pathology-in-high-risk-prostate-cancer-implications-for-better-risk-stratification-and-preoperative-prediction-of-oncologic-outcomes
#2
Seung-Kwon Choi, Myungsun Shim, Myong Kim, Myungchan Park, Sangmi Lee, Cheryn Song, Hyung-Lae Lee, Hanjong Ahn
PURPOSE: To evaluate the better risk stratification based on surgical pathology, and to predict oncologic outcomes after radical prostatectomy (RP) with a better scoring system in high-risk prostate cancer (PCa) patients. METHODS: We evaluated high-risk PCa patients (PSA >20 ng/ml, ≥cT3a, or Gleason score 8-10) who underwent RP between 2007 and 2013 at our institute. We classified patients into three groups according to their pathologic outcomes: favorable (pT2, Gleason score ≤7, and node negative), intermediate (specimen-confined disease (pT2-3a, node negative PCa with negative surgical margins) but not in the favorable group), and unfavorable (the remaining patients)...
May 18, 2017: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/28515927/body-mass-index-as-a-classifier-to-predict-biochemical-recurrence-after-radical-prostatectomy-in-patients-with-lower-prostate-specific-antigen-levels
#3
Keisuke Goto, Hirotaka Nagamatsu, Jun Teishima, Yuki Kohada, Shinsuke Fujii, Yoshimasa Kurimura, Koji Mita, Masanobu Shigeta, Satoshi Maruyama, Yoji Inoue, Mitsuru Nakahara, Akio Matsubara
Prostate cancer, one of the most common malignant tumors among men, is closely associated with obesity and, thus far, several studies have suggested the association between obesity and aggressive pathological characteristics in the United States. However, the effect of obesity on prostate cancer mortality is controversial, and it remains unclear whether obesity contributes to the aggressiveness of prostate cancer in Asian patients. The aim of the present study was to investigate the association between body mass index (BMI) and the clinicopathological characteristics of prostate cancer in 2,003 Japanese patients who underwent radical prostatectomy...
May 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28514930/hypofractionated-stereotactic-body-radiotherapy-for-localized-prostate-cancer-first-nordic-clinical-experience
#4
Kristiina Koskela, Jan-Erik Palmgren, Janne Heikkilä, Heli Virsunen, Liisa Sailas, Päivi Auvinen, Jan Seppälä, Vesa Kataja
BACKGROUND: The use of hypofractionated stereotactic body radiotherapy (SBRT) as primary treatment modality in clinically localized prostate cancer (PCa) is emerging, because the low α/β-ratio favors the use of high dose per fraction in PCa. There is a need for more data about SBRT, especially in high-risk PCa patients. The purpose of this retrospective study was to evaluate the safety and the short-term efficacy of robotic SBRT in a clinical patient cohort with localized PCa including also high-risk patients (D'Amico risk stratification)...
July 2017: Acta Oncologica
https://www.readbyqxmd.com/read/28511371/study-of-serum-total-psa-and-free-psa-as-an-oncological-marker-in-breast-tumour
#5
Elteza Tahjiba Jahir, Runi Devi, Bibhuti Bhushan Borthakur
INTRODUCTION: Breast Cancer (BC) cases are rising alarmingly all over the world and India is not an exception. This rising trend is due to an increased age at first child birth, decreased breast feeding, and the changing lifestyle mostly in urban India. With the advent of more sensitive methodologies and research works in this field, it has been suggested that Prostate Specific Antigen (PSA) plays an important role in the pathogenesis of breast cancer besides other established tumour markers...
March 2017: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/28502694/phase-ii-trial-of-the-pi3-kinase-inhibitor-buparlisib-bkm-120-with-or-without-enzalutamide-in-men-with-metastatic-castration-resistant-prostate-cancer
#6
Andrew J Armstrong, Susan Halabi, Patrick Healy, Joshi J Alumkal, Carolyn Winters, Julie Kephart, Rhonda L Bitting, Carey Hobbs, Colleen F Soleau, Tomasz M Beer, Rachel Slottke, Kelly Mundy, Evan Y Yu, Daniel J George
BACKGROUND: Phosphatidylinositol-3-kinase (PI3K) and androgen receptor pathway activation is common in metastatic castration resistant prostate cancer (mCRPC). Buparlisib is an oral, pan-class I PI3 kinase inhibitor. METHODS: This was a multisite single arm phase II trial of buparlisib 100 mg ± enzalutamide daily in men with mCRPC whose disease progressed on or who were not candidates for docetaxel. The primary end-point was the rate of radiographic/clinical progression-free survival (PFS) at 6 months...
May 11, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28490387/serum-carotenoid-and-retinol-levels-in-african-caribbean-tobagonian-men-with-high-prostate-cancer-risk-in-comparison-with-african-american-men
#7
Alicia C McDonald, Clareann H Bunker, Jay Raman, John Richie, Alan L Patrick
Black men are known to have a higher risk for prostate cancer (PC). Carotenoids and retinol, linked to PC, have not been compared in different black populations at risk. We examined serum carotenoid and retinol levels between PC-free African-Caribbean (AC) Tobagonian men with a high PC risk (high-grade prostatic intraepithelial neoplasia, atypical foci or repeated abnormal PC screenings) and African-American (AA) men with elevated serum prostate-specific antigen (PSA) levels (≥4 ng/ml). AC men who participated in the 2003 lycopene clinical trial and AA men who participated in the 2001-2006 National Health and Nutrition Examination Survey were compared...
May 11, 2017: British Journal of Nutrition
https://www.readbyqxmd.com/read/28488030/-125-i%C3%A2-brachytherapy-in-younger-prostate-cancer-patients-outcomes-in-low-and-intermediate-risk-disease
#8
Isabelle Kindts, Karin Stellamans, Ignace Billiet, Hans Pottel, Antoon Lambrecht
PURPOSE: To evaluate local recurrence in younger men treated with low-dose-rate (LDR) (125)I brachytherapy (BT) for localized prostate cancer. PATIENTS AND METHODS: A total of 192 patients (≤65-years-old) were treated with LDR (125)I-BT ± hormone therapy. Local failure was defined as any prostate-specific antigen (PSA) rise leading to salvage treatment or biochemical failure according to the Phoenix definition. A bounce was defined as a rise in the nadir of ≥0...
May 9, 2017: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/28481440/prognostic-utility-of-biopsy-derived-cell-cycle-progression-score-in-patients-with-nccn-low-risk-prostate-cancer-undergoing-radical-prostatectomy-implications-for-treatment-guidance
#9
Jeffrey T Tosoian, Meera R Chappidi, Jay T Bishoff, Stephen J Freedland, Julia Reid, Michael Brawer, Steven Stone, Thorsten Schlomm, Ashley E Ross
OBJECTIVES: To determine the prognostic utility of the Cell Cycle Progression (CCP) score in men with National Comprehensive Cancer Network (NCCN) low-risk prostate cancer who underwent radical prostatectomy (RP). PATIENTS AND METHODS: Patients who underwent RP for Gleason score ≤6 prostate cancer at three institutions (Martini Clinic [MC], Durham Veterans Affairs Medical Center [DVA], and Intermountain Healthcare [IHC]) were identified. The CCP score was obtained from diagnostic (DVA, IHC) or simulated biopsies (MC)...
May 8, 2017: BJU International
https://www.readbyqxmd.com/read/28478884/abiraterone-acetate-for-treatment-of-metastatic-castration-resistant-prostate-cancer-in-chemotherapy-naive-patients-an-italian-analysis-of-patients-satisfaction
#10
Luca Cindolo, Clara Natoli, Cosimo De Nunzio, Michele De Tursi, Maurizio Valeriani, Silvana Giacinti, Salvatore Micali, Mino Rizzo, Giampaolo Bianchi, Eugenio Martorana, Marcello Scarcia, Giuseppe Mario Ludovico, Pierluigi Bove, Anastasia Laudisi, Oscar Selvaggio, Giuseppe Carrieri, Maida Bada, Pietro Castellan, Luca Topazio, Stefano Boccasile, Pasquale Ditonno, Paolo Chiodini, Luigi Schips
INTRODUCTION: Abiraterone acetate (AA) gives a significant improvement in survival for patients with metastatic castration-resistant prostate cancer (mCRPC) before and after chemotherapy and has a favorable effect on patients' health-related quality of life and pain. Only a few studies have investigated patient-reported outcomes (PROs) in AA treatment for mCRPC. The aim of this study was to investigate patients' satisfaction in men affected by mCRPC treated with AA. MATERIALS AND METHODS: This was a retrospective analysis of a database of consecutive chemonaive patients with progressive mCRPC...
April 11, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28472366/androgen-receptor-gene-status-in-plasma-dna-associates-with-worse-outcome-on-enzalutamide-or-abiraterone-for-castration-resistant-prostate-cancer-a-multi-institution-correlative-biomarker-study
#11
V Conteduca, D Wetterskog, M T A Sharabiani, E Grande, M P Fernandez-Perez, A Jayaram, S Salvi, D Castellano, A Romanel, C Lolli, V Casadio, G Gurioli, D Amadori, A Font, S Vazquez-Estevez, A González Del Alba, B Mellado, O Fernandez-Calvo, M J Méndez-Vidal, M A Climent, I Duran, E Gallardo, A Rodriguez, C Santander, M I Sáez, J Puente, D Gasi Tandefelt, A Wingate, D Dearnaley, F Demichelis, U De Giorgi, E Gonzalez-Billalabeitia, G Attard
Background: There is an urgent need to identify biomarkers to guide personalized therapy in castration-resistant prostate cancer (CRPC). We aimed to clinically qualify androgen receptor (AR) gene status measurement in plasma DNA using multiplex droplet digital PCR (ddPCR) in pre- and post-chemotherapy CRPC. Methods: We optimized ddPCR assays for AR copy number and mutations and retrospectively analyzed plasma DNA from patients recruited to one of the three biomarker protocols with prospectively collected clinical data...
May 3, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28471803/search-for-genetic-factor-association-with-cancer-free-prostate-specific-antigen-level-elevation-on-the-basis-of-a-genome-wide-association-study-in-the-korean-population
#12
Eun Kyung Choe, Young Lee, Jeong Yeon Cho, Seung Ho Choi, Boram Park, Jong-Eun Lee, Eun Young Cho
We investigated the genetic markers associated with elevated serum prostate-specific antigen (sPSA) levels to improve the predictive power of sPSA in screening for prostate cancer. A genome-wide association study was carried out among 4124 healthy Korean male adults using the Affymetrix Axiom Customized Biobank Genotyping Arrays for sPSA levels. A subgroup analysis for increased sPSA levels who underwent a prostate biopsy (n=64) was also carried out. We detected 11 single nucleotide polymorphisms (SNPs) near the Solute carrier family 45member 3, AGAP7P, MSMB, LOC101929917, and KLK3 genes associated with sPSA levels...
May 3, 2017: European Journal of Cancer Prevention
https://www.readbyqxmd.com/read/28465697/the-effect-of-urethral-catheterization-on-the-level-of-prostate-specific-antigen
#13
Mohammad Hossein Izadpanahi, Hojatollah Salimi, Amir Javid, Salman Eslami
BACKGROUND: The normal prostate-specific antigen (PSA) level in patients with urethral catheterization is a controversy. We designed this study to investigate the effect of nontraumatic urethral catheterization without urinary retention on serum PSA. MATERIALS AND METHODS: Seventy patients scheduled for urethral catheterization before elective surgeries were randomly selected and included in the study. They were categorized into two age groups: 40-60 years (Group A) and over 60 years (Group B)...
2017: Journal of Research in Medical Sciences: the Official Journal of Isfahan University of Medical Sciences
https://www.readbyqxmd.com/read/28464446/unification-of-favorable-intermediate-unfavorable-intermediate-and-very-high-risk-stratification-criteria-for-prostate-cancer
#14
Zachary S Zumsteg, Michael J Zelefsky, Kaitlin M Woo, Daniel E Spratt, Marisa A Kollmeier, Sean McBride, Xin Pei, Howard M Sandler, Zhigang Zhang
OBJECTIVE: To improve on the existing risk-stratification systems. PATIENTS AND METHODS: This was a retrospective investigation including 2248 patients undergoing dose-escalated external beam radiotherapy (EBRT) at a single institution. We separated National Comprehensive Cancer Network (NCCN) intermediate-risk prostate cancer into favorable and unfavorable groups based on primary Gleason pattern, percentage of positive biopsy cores (PPBC), and number of NCCN intermediate-risk factors...
May 2, 2017: BJU International
https://www.readbyqxmd.com/read/28463149/duration-of-androgen-deprivation-in-locally-advanced-prostate-cancer-long-term-update-of-nrg-oncology-rtog-9202
#15
Colleen A F Lawton, Xiaolei Lin, Gerald E Hanks, Herbert Lepor, David J Grignon, Harmar D Brereton, Meena Bedi, Seth A Rosenthal, Kenneth L Zeitzer, Varagur M Venkatesan, Eric M Horwitz, Thomas M Pisansky, Harold Kim, Matthew B Parliament, Rachel Rabinovitch, Mack Roach, Young Kwok, James J Dignam, Howard M Sandler
PURPOSE: Trial RTOG 9202 was a phase 3 randomized trial designed to determine the optimal duration of androgen deprivation therapy (ADT) when combined with definitive radiation therapy (RT) in the treatment of locally advanced nonmetastatic adenocarcinoma of the prostate. Long-term follow-up results of this study now available are relevant to the management of this disease. METHODS AND MATERIALS: Men (N=1554) with adenocarcinoma of the prostate (cT2c-T4, N0-Nx) with a prostate-specific antigen (PSA) <150 ng/mL and no evidence of distant metastasis were randomized (June 1992 to April 1995) to short-term ADT (STAD: 4 months of flutamide 250 mg 3 times per day and goserelin 3...
June 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28462945/select-men-benefit-from-androgen-deprivation-therapy-delivered-with-salvage-radiation-therapy-after-prostatectomy
#16
E B Holliday, D A Kuban, L B Levy, Y Bolukbasi, P Master, S Choi, Q Nguyen, S E McGuire, U Mahmood, S J Frank, K E Hoffman
BACKGROUND: Which men benefit most from adding androgen deprivation therapy (ADT) to salvage radiation therapy (SRT) after prostatectomy has not clearly been defined; therefore, we evaluated the impact of ADT to SRT on failure-free survival (FFS) in men with a rising or persistent PSA after prostatectomy. METHODS: We identified 332 men who received SRT after prostatectomy from 1987 to 2010. Recursive partitioning analysis (RPA) identified favorable, intermediate and unfavorable groups based on the risk of failure after SRT alone...
May 2, 2017: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/28462855/benefits-of-using-stereotactic-body-radiotherapy-in-patients-with-metachronous-oligometastases-of-hormone-sensitive-prostate-cancer-detected-by-18f-fluoromethylcholine-pet-ct
#17
Esther W Bouman-Wammes, Joyce M van Dodewaard-De Jong, Max Dahele, Matthijs C F Cysouw, Otto S Hoekstra, R Jeroen A van Moorselaar, Maartje A H Piet, Hein J Verberne, Adriaan D Bins, Henk M W Verheul, Ben J Slotman, Daniela E Oprea-Lager, Alfons J M Van den Eertwegh
INTRODUCTION: For patients with oligometastatic recurrence of prostate cancer (PC), stereotactic body radiation therapy (SBRT) represents an attractive treatment option, as it is safe without major side effects. The aim of this study was to investigate the impact of SBRT in delaying the start of androgen deprivation therapy (ADT). PATIENTS AND METHODS: Forty-three patients treated with SBRT for oligometastatic recurrence (< 5 metastases) of hormone-sensitive PC, defined with [(18)F]fluoromethylcholine positron emission tomography/computed tomography were included...
March 29, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28460801/obesity-is-associated-with-biochemical-recurrence-after-radical-prostatectomy-a-multi-institutional-extended-validation-study
#18
Agnes B Maj-Hes, Romain Mathieu, Mehmet Özsoy, Francesco Soria, Marco Moschini, Mohammad Abufaraj, Alberto Briganti, Morgan Roupret, Pierre I Karakiewicz, Tobias Klatte, Shahrokh F Shariat
BACKGROUND: There are no clear data regarding the association between body mass index (BMI) and outcomes after radical prostatectomy (RP). This study aimed to investigate the association between BMI and biochemical recurrence (BCR) after RP in a large international contemporary cohort of patients with prostate cancer. METHODS: We retrospectively analyzed data from 6,519 patients who underwent RP at 5 institutions. BMI was analyzed as both a continuous and categorical variable (<25kg/m(2), 25-29...
April 28, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28460462/the-prognostic-role-of-immune-checkpoint-markers-programmed-cell-death-protein-1-pd-1-and-programmed-death-ligand-1-pd-l1-in-a-large-multicenter-prostate-cancer-cohort
#19
Nora Ness, Sigve Andersen, Mehrdad Rakaee Khanehkenari, Cecilie V Nordbakken, Andrej Valkov, Erna-Elise Paulsen, Yngve Nordby, Roy M Bremnes, Tom Donnem, Lill-Tove Busund, Elin Richardsen
Programmed cell death protein 1 (PD-1) and its ligand Programmed death ligand 1 (PD-L1) have gained massive attention in cancer research due to recent availability and their targeted antitumor effects. Their role in prostate cancer is still undetermined. We constructed tissue microarrays from prostatectomy specimens from 535 prostate cancer patients. Following validation of antibodies, immunohistochemistry was used to evaluate the expression of PD-1 in lymphocytes and PD-L1 in epithelial and stromal cells of primary tumors...
April 18, 2017: Oncotarget
https://www.readbyqxmd.com/read/28457109/salvage-radiation-therapy-for-biochemical-failure-following-radical-prostatectomy
#20
Benjamin Spieler, Jeffrey Goldstein, Yaacov R Lawrence, Akram Saad, Raanan Berger, Jacob Ramon, Zohar Dotan, Menachem Laufer, Ilana Weiss, Lev Tzvang, Philip Poortmans, Zvi Symon
BACKGROUND: Radiotherapy to the prostate bed is used to eradicate residual microscopic disease following radical prostatectomy for prostate cancer. Recommendations are based on historical series. OBJECTIVES: To determine outcomes and toxicity of contemporary salvage radiation therapy (SRT) to the prostate bed. METHODS: We reviewed a prospective ethics committee-approved database of 229 patients referred for SRT. Median pre-radiation prostate-specific antigen (PSA) was 0...
January 2017: Israel Medical Association Journal: IMAJ
keyword
keyword
25554
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"